Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration by Kenchappa, Rajappa S. et al.
The FASEB Journal • FJ Express
Estrogen and neuroprotection: higher constitutive
expression of glutaredoxin in female mice offers
protection against MPTP-mediated
neurodegeneration
RAJAPPA S. KENCHAPPA,*,†,1 LATHA DIWAKAR,*,†,1 JAYASREE ANNEPU,† AND
VIJAYALAKSHMI RAVINDRANATH*,†,2
*Division of Molecular and Cellular Neuroscience, National Brain Research Centre, Nainwal Mode,
Manesar, India; and †Department of Neurochemistry, National Institute of Mental Health and
Neurosciences, Bangalore, India
To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.03-1075fje;
doi: 10.1096/fj.03-1075fje
SPECIFIC AIMS
MPTP, a dopaminergic neurotoxin, acts through inhi-
bition of mitochondrial complex I, which produces
Parkinson’s disease-like symptoms in primates, includ-
ing humans. Epidemiological studies have shown that
the risk/incidence of Parkinson’s disease in men is
nearly twice that of women. Although the neuroprotec-
tive effect of estrogen is known, its mode of action is not
well understood. We therefore examined the molecular
mechanisms underlying the neuroprotection seen in
female mice using MPTP as a model dopaminergic
neurotoxin.
PRINCIPAL FINDINGS
1. Female mice are resistant to MPTP neurotoxicity
Male and female mice were administrated of MPTP (30
mg/kg body wt, s.c) as a single dose or daily for 8 days
and complex I activity was measured in striatum and
midbrain. After acute and chronic administration of
MPTP, complex I activity was significantly decreased in
striatum and midbrain of male mice while there was no
change in females (Fig. 1a). After 8 days of chronic
MPTP exposure, the brains were removed from male
and female mice and coronal sections were cut from
the anteroposterior middle area of the substantia nigra
para compacta. Morphological evaluation of dopami-
nergic neurons was performed by immunostaining for
tyrosine hydroxylase. Tyrosine hydroxylase staining was
nearly undetectable in the substantia nigra of male
mice, indicating loss of dopaminergic neurons; in fe-
male mice the immunostaining was similar to controls,
indicating that the dopaminergic neurons in females
were unaffected by chronic administration of MPTP
(Fig. 1b).
2. Total GSH levels and glutaredoxin (Grx1)
expression are unaltered in female mouse brain
after MPTP administration
In male mice, total GSH levels in striatum and midbrain
decreased significantly after a single dose of MPTP but
were unaffected in female mice. However, GSSG levels
in the striatum and midbrain of female mice signifi-
cantly increased 4 h after MPTP treatment (101% and
65% higher than corresponding controls, respectively),
indicating the generation of oxidative stress in female
mice. We had earlier demonstrated that Grx1 is impor-
tant for maintaining the functional integrity of com-
plex I and its up-regulation is required for the recovery
of mitochondrial complex I activity after a single dose
of MPTP in male mice. We examined the expression of
Grx1 mRNA and measured the activity of Grx1 in the
striatum and midbrain of male and female mice after a
single dose of MPTP. mRNA levels and Grx1 activity
were significantly increased after a single dose of MPTP
treatment in male mice and unaltered in female mice at
all time points examined.
3. Redox-sensitive transcription factor AP1 is not
activated in female mouse brain regions after MPTP
administration
AP1 is a redox-sensitive transcription factor whose
activity is modulated by agents that promote intracellu-
lar thiol perturbation. AP1 activation was significantly
increased in striatum and midbrain of male mice within
30 min after a single exposure to MPTP whereas AP1
activation was unaffected in females vs. untreated con-
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trols. Thus, the earliest response to MPTP toxicity—
activation of AP1—was not seen in female mice whereas
in male mice a series of events, starting with AP1
activation 30 min after MPTP administration.
4. Blockade of estrogen receptors by ICI 182,780
renders female mice vulnerable to MPTP toxicity
Sagittal slices of female mouse brain were preincubated
with ICI 182,780, an estrogen receptor antagonist (1
nM), for 0.5 h, followed by incubation with MPTP (1
nM) for 1 h. Pretreatment with ICI 182,780 abolished
the neuroprotection in females and significant inhibi-
tion of complex I activity was seen. When female mice
were pretreated with ICI 182,780 (1 mg/kg body wt/
day, s.c) for 15 days and MPTP was administered as a
single dose (30 mg/kg body wt, s.c) or daily for 8 days,
significant inhibition of complex I activity was seen in
striatum and midbrain. Thus, blockade of estrogen
receptors by ICI 182,780 abolished the gender differ-
ence typically seen after MPTP administration and
rendered female mice sensitive to MPTP toxicity.
5. Glutaredoxin expression in female mouse brain is
down-regulated by estrogen receptor antagonist ICI
182,780
Constitutive activity of Grx1 in striatum and midbrain
of female mice was significantly higher than in males.
After blockade of estrogen receptors with ICI 182,780,
Grx1 activity in striatum and midbrain of female mice
decreased significantly (Fig. 2b). ICI 182,780 treatment
had no effect on Grx1 expression in liver (Fig. 2b, LV).
Figure 2. Higher constitutive activity of glutaredoxin in
females is down-regulated by estrogen receptor antagonist ICI
182,780 treatment. a) Glutaredoxin activity was measured in
striatum (ST) and midbrain (MB) of male (blank bars)/
female mice (filled bars) and is expressed as % control of
corresponding activity in male mouse brain regions. Values
are mean  se (n3 animals). Glutaredoxin activity in
striatum and midbrain from male animals was 17.92  1.40
and 36.45  3.42 nmol of NADPH oxidized min–1 mg pro-
tein–1, respectively. *Values significantly different from corre-
sponding controls (P0.002). b) Female mice were treated
with ICI 182,780 (1 mg/kg body wt, s.c) daily for 15 days
(filled bars); control animals received vehicle alone (blank
bars). Glutaredoxin activity was measured in striatum (ST),
midbrain (MB), and liver (LV) and is expressed as % control.
Values are mean  se (n3 animals). *Significantly different
from vehicle-treated controls (P0.003).
Figure 1. Effect of MPTP on complex I activity (a) and on
dopaminergic neurons (b) in male and female mice. a) Male
and female mice were administered a single dose of MPTP
(30 mg/kg body wt, s.c). Animals were killed after 30 h (gray
bars). Animals were also treated with MPTP (30 mg/kg body
wt/day, s.c) daily for 8 days (filled bars) and killed 24 h after
the last dose. Control animals received vehicle alone (blank
bars). Complex I activity was estimated in striatum (ST) and
midbrain (MB) of male and female mice and is expressed as
nmol of NADH oxidized min–1 mg protein–1. Values are
mean  se (n5 animals). *Significantly different from
vehicle-treated controls (P0.002). b) Immunohistochemical
localization of tyrosine hydroxylase in dopaminergic neurons
of substantia nigra of male (C, D) and female (A, B) mice
after treatment with vehicle (A, C) or MPTP (30 mg/kg body
wt/day, s.c) daily for 8 days (B, D). Scale bar  50 m.
1103GLUTAREDOXIN REGULATION BY ESTROGEN
CONCLUSIONS AND SIGNIFICANCE
Female mice are resistant to the mitochondrial dysfunc-
tion and dopaminergic cell loss seen in brain regions of
male mice after MPTP exposure. In the present study,
we have examined the early events after MPTP admin-
istration in male and female mice with the aim to
identify the critical entities that confer neuroprotection
to females. The sequential events observed in striatum
and midbrain of male mice after a single dose of MPTP
include activation of AP1 after 30 min, followed by loss
of GSH, inhibition of mitochondrial complex I and
up-regulation of Grx1 mRNA and protein. None of
these events were observed in the female mice under
similar conditions.
Pretreatment with ICI 182,780, a classical antagonist
of  and  estrogen receptors, abolishes the neuropro-
tection seen in female mice, both in vitro in brain slices
and in vivo, and renders them vulnerable to MPTP
toxicity. The male mice are unaffected by ICI 182,780,
indicating that the observed effect of ICI 182,780 on
female mice is through its preferential action on estro-
gen receptors.
The primary mechanism of MPTP toxicity is through
inhibition of complex I leading to mitochondrial dys-
function, followed by cell death. Inhibition of complex
I by MPP involves oxidation of essential thiol groups
in the subunits of complex I by glutathionylation since
it has several critical thiol groups in its active site. After
the neurotoxic insult, Grx1 (which specifically reduces
glutathionylated proteins to thiols) is up-regulated and
aids recovery of mitochondrial complex I function, and
down-regulation of Grx1 prevents the recovery of mito-
chondrial complex I function after MPTP exposure.
Grx1 is critical for maintenance of the mitochondrial
complex I under normal conditions and for recovery
after neurotoxic insult.
Gender difference is not seen in the constitutive
expression of -glutamyl cysteine synthetase, the critical
enzyme involved in GSH synthesis or in the constitutive
levels of GSH. However, Grx1 is expressed constitu-
tively at higher levels in female mice CNS regions, such
as striatum and midbrain, than in corresponding levels
in males (Fig. 2a). Grx1 activity is down-regulated by
pretreating mice with the estrogen antagonist ICI
182,780, indicating that Grx1 expression is regulated
through estrogen receptors. The effect of ICI 182,780
on Grx1 was limited to brain regions and not seen in
liver although estrogen receptors are present in liver
and the expression of several genes is regulated
through these receptors. Our observations are in con-
cordance with the fact that protective effect of estrogen
is not universal, but restricted to certain tissues such as
brain.
Estrogen response element (ERE) sequence is not
present upstream of Grx1 gene. However, recent re-
ports have demonstrated that gene expression driven
by estrogen receptor could occur through a direct
protein–protein interaction of ligand-bound estrogen
receptor with transcription factors such as SP1 and
EPRE in the absence of ERE. An SP1 binding site is
present upstream of the Grx1 gene, indicating such
mechanisms could drive Grx1 expression; potentially,
this could explain the higher levels of Grx1 in female
mouse brain regions.
In the present study we demonstrate the increased
expression of Grx1 in female mice brain regions such as
striatum and midbrain, which may be involved in
estrogen-mediated neuroprotection. It is debatable
whether other brain regions such as hippocampus,
which are vulnerable to neurotoxic damage (including
excitotoxicity) exhibit a similar response. Individual
brain regions respond very differently and potentially
differential levels of Grx1 expression or turnover may
contribute and define the final outcome. In addition to
neurotrophic factors, structural proteins and anti-apop-
totic factors, thiol disulfide oxido-reductase (Grx1) may
represent a new class genes that are regulated by
estrogen and are involved in neuroprotection, particu-
larly those related to protein thiol oxidation leading to
mitochondrial dysfunction.
Figure 3. Schematic illustration depict-
ing the regulation of glutaredoxin (a
thiol disulfide oxido-reductase) expres-
sion by estrogen and its involvement in
neuroprotection related to protein thiol
oxidation, leading to mitochondrial
complex I dysfunction. Glutaredoxin is
essential for maintenance of mitochon-
drial complex I activity under normal
conditions and during oxidative stress.
Glutaredoxin activity is higher in fe-
males than in males; ICI 182,780, an
estrogen antagonist, down-regulates
glutaredoxin expression and abolishes
the gender difference. Increased activity
of glutaredoxin may contribute to the
neuroprotection seen in females after
MPTP exposure and potentially the dys-
function of mitochondrial complex I
commonly seen in Parkinson’s disease.
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